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Hypoferremia is a common response to systemic infections or infl ammation characterized by iron sequestration in its stores as a protective mechanism and manifestation of anemia. 1, 2 The proinfl ammatory cytokine interleukin-6 (IL-6) plays a key role in anemia of chronic disease (ACD), also called anemia of infl ammation, through induction of the iron-regulatory hormone hepcidin, which is responsible for most of the disorders in anemia of chronic infl ammatory processes. 3 Hepcidin is a peptide hormone secreted by the liver in response to infl ammatory stimuli and iron overload. It is synthesized as a preproform -preprohepcidin composed of 84 amino acids. 4, 5 Rheumatoid arthritis (RA) is a systemic autoimmune disease that involves a chronic, progressive infl ammation. The changes in iron homeostasis in RA may be due to ACD, iron defi ciency anemia (IDA) or both. [6] [7] [8] [9] As anemia in RA may cause severe symptoms and aggravation of other diseases manifestations, early detection of anemia is of vital importance. 9 Transferrin receptor is a membrane glycoprotein composed of two monomers bound together by two disulfi de bonds. The content of the soluble form of the receptor sTfR in plasma is proportional to the amount of transferrin on the surface of hematopoietic cells 10 and refl ects the extent of iron defi ciency. The advantage of measuring sTfR is that there are only two conditions related to high sTfR: 1) increased production of erythrocytes and; 2) tissue iron defi ciency. 11 There is no clear evidence in literature concerning the diagnostic value of sTfR 12, 13 and serum ferritin 14 . Also, the comments on the associations of iron homeostasis parameters with markers of infl ammatory activity and autoimmune disorders in RA differ from one another. [15] [16] [17] [18] This can possibly be accounted for by differences in the number of patients, their involvement in common groups with rheumatology diseases or the usage of different methods for evaluation.
AIM
The aim of the study was to fi nd the correlations between the parameters of iron homeostasis, infl ammatory activity and autoimmune disorders in rheumatoid arthritis (RA).
MATERIALS AND METHODS

PATIENTS
The present study included 114 patients with RA (16 males and 98 females, mean age 58 ± 10 yrs,) and 42 healthy controls. All patients were diagnosed as having RA according to EULAR 2010 criteria. 19, 20 The patients included in the present study had moderate (3.2<DAS 28≤5.1) and high (DAS 28>5.1) disease activity.
We used the World Health Organization (WHO) defi nitions of anemia as a hemoglobin threshold of < 12 g/dl in women, and < 13 g/dl in men. On the basis of these criteria the patients were distributed in two subgroups. The fi rst group was composed of 79 non-anemic patients and the second group was made up of 35 patients who fulfi lled the criteria for anemia.
We determined the parameters of disease activity and autoimmune disorders -disease activity score 28 (DAS 28): 5.7 ± 1.2, n = 114; RF: 56 (20 -198) , n = 107; antiCCP antibodies: 140 (54 -246), n = 67.
All patients received NSAIDs and additional therapy as follows: DMARDs (n = 83), DMARDs and corticosteroids (n = 10), biological agents, DMARDs and corticosteroids (n = 4), corticosteroids (n = 2), biological agents and DMARDs (n = 11), biological agents and corticosteroids (n = 3). All patients on treatment with methotrexate alone or in combination were receiving folic acid and the mean ± SD of MCV, MCH and MCHC were: 89 ± 7, fl ; 29 ± 3, pg; 320 ± 34, g/l, respectively. These results excluded folate defi ciency and megaloblastic anemia.
The study was approved by the ethics committee of Medical University of Plovdiv. All participants gave informed consent before being recruited for the study.
LABORATORY ANALYSIS
The following parameters were determined: for iron homeostasis -serum iron, total iron binding capacity (TIBC), ferritin, sTfR; for infl ammatory activity -C-reactive protein (CRP), IL-6, prohepcidin; for autoimmune disorders -RF, antiCCP, DAS 28.
Laboratory tests such as erythrocyte count, hemoglobin (Hb), erythrocyte sedimentation rate (ESR), TIBC were performed using standard laboratory methods.
Serum ferritin, sTfR, CRP, IL-6 were determined using commercially available kits (BioVendor -Laboratornimedicina, Czech Republic) by ELISA. The concentration of serum prohepcidin was measured by ELISA using a commercial kit (DRG Instruments, GmbH, Germany), according to the manufacturer's instructions. RF was determined with ELISA kits (Nova Tec Immundiagnostica, GmbH, Germany) and antiCCP with ELISA kits (Eurodiagnostica, Sweden).
STATISTICS
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). The concentrations of the parameters of iron homeostasis, infl ammation and autoimmune disorders were tested for normality with Kolmogorov-Smirnov test. Data were given as mean ± SD or as median and 25 thpercentile and 75 th -percentile. T-test was used to compare two groups with normal distribution and Mann-Whitney U test was used to compare groups with non-normal distribution. Correlations between data were evaluated by calculating the Pearson's or Spearman's correlation coeffi cient depending on the distribution of the continuous variables. P<0.05 was considered as statistically signifi cant. Table 1 shows the comparison between parameters of iron homeostasis and infl ammation in patients with RA and healthy controls. The sTfR, CRP, IL-6 and prohepcidin levels were signifi cantly higher in the RA group than in the control group while the level of serum iron was signifi cantly higher in controls compared to RA. No signifi cant difference was Folia Medica I 2018 I Vol. 60 I No. 1 found in ferritin level and TIBC between healthy controls and RA patients. Table 2 presents the comparison between parameters of iron homeostasis and infl ammation in patients with RA according to the level of Hb. On the basis of these criteria the patients were distributed in two subgroups (No anemia and Anemia). The levels of CRP, IL-6 and probably sTfR (P = 0.052) were signifi cantly higher in the group with anemia compared to the one without anemia. Serum iron was signifi cantly higher in the group without anemia. Table 3 shows the comparison between parameters of iron homeostasis and infl ammation in patients with RA according to the degree of disease activity (DAS 28). The level of CRP was signifi cantly higher in the subgroup with high disease activity (DAS 28>5.1) compared to the subgroup with moderate disease activity (3.2<DAS 28≤5.1). No signifi cant difference was found in the level of sTfR, ferritin, IL-6 and prohepcidin in the two subgroups. TIBC and probably serum iron (P = 0.051) were signifi cantly lower in the subgroup with high disease activity. Table 4 shows the correlations between parameters of iron homeostasis and infl ammation in RA patients and healthy controls. Table 5 shows the correlations between parameters of infl ammation and autoimmune disorders in patients with RA. Table 6 shows the correlations between parameters of iron homeostasis, infl ammation and autoimmune disorders in patients with RA. In RA patients the mean of Hb was 126.45 ± 13.05, n = 114 and the median of RBC: 4.44 (4.16 -4.72), n = 106. We found the following positive correlations: serum iron and Hb (n = 57, r = 0.457, P<0.001); serum iron and RBC (n = 53, r = 0.450, P = 0.001); Hb and RBC (n = 106, r = 0.628, P<0.001). Hb and RBC negatively correlated with fi brinogen (Table 6 ). The level of Hb negatively correlated with ESR, CRP and IL-6 (Table 6) . DISCUSSION ACD may be diagnosed by determination of serum parameters of iron homeostasis -serum iron, TIBC (saturation of transferrin with iron), transferrin concentration, ferritin and sTfR. 17 In RA the form of anemia may be ACD, IDA or both (ACD + IDA). Since anemia in RA may cause severe complications, researchers are making efforts to fi nd appropriate methods for early detection, monitoring and treatment of the condition. Unlike "pure iron defi ciency", in anemia of chronic infl ammation, the target for therapy is the major disease process. 21, 22 The sTfR level in serum is considered a key marker in ACD research. 23 The studies show also that sTfR is a reliable laboratory index of IDA and in distinguishing IDA from ACD. 13 According to some authors, anemia of chronic infl ammation Prohepcidin, ng/ml 1103 ± 651 n=38 1341 ± 852 n=76 NS proceeds with decreased level of sTfR and that distinguishes it from the anemia caused by insuffi cient dietary intake of iron. 21 Other authors report that increased level of sTfR is a feature of functional iron defi ciency, despite the adequate iron stores as it is in chronic infl ammatory processes. 24 Our results confi rm the latter fi nding (Table 1) . Iron defi ciency in RA is confi rmed by the increase of sTfR level not only in patients compared to controls but also in the subgroup with anemia compared to the subgroup without anemia ( Table 2 ). The study of the correlations of sTfR with the other parameters of iron homeostasis, infl ammatory activity and autoimmune disorders show that sTfR provides most (Tables 4 and 6 ). The comparison with healthy controls clearly indicates that only in RA there is a positive correlation of iron requirement (sTfR) with the release of the proinfl ammatory cytokine IL-6 and the hormone hepcidin (assessed by the prohepcidin content) ( Table 4 ). The same associations are observed between sTfR and the parameters of evaluation of the disorders in RA -DAS 28, ESR, RF and antiCCP (Table 6 ). The negative correlation of serum iron with sTfR level also confi rms the informative value of the parameter -the adaptive pathologic mechanism of iron sequestration in its stores, due to the chronic infl ammation in RA, causes cellular iron defi ciency and in response the cells increase the expression of transferrin receptors. Such correlation was not observed in the control group (Table 4) . The individual acute phase proteins provide less information for evaluation of the disease process in RA. Therefore specifi c parameters that comprise these proteins in total are accepted. An example of such a parameter is DAS 28. 25 Probably because ferritin is both an iron binding protein and an acute phase protein 14 , its informative value for evaluation of iron homeostasis in RA is limited. Some authors report that ferritin level is signifi cantly higher in RA patients compared to controls and is positively associated with DAS 28. 26 In our study no signifi cant difference was found in ferritin level between healthy controls and RA patients although the median in the RA group was higher ( Table 1) . The results we obtained showed no signifi cant association of sTfR and serum iron with serum ferritin in RA, while in healthy controls ferritin positively correlated with serum iron and refl ected iron stores (Table 4) . Serum ferritin had a negative correlation with TIBC in RA which indicated inability for usage of the stored iron (Table 4) . A negative correlation of TIBC with serum ferritin and CRP (Table  4 ) and with specifi c rheumatoid disorders DAS 28 and antiCCP was found in RA patients only (Table  6 ). These results indicated that TIBC refl ected the grade of infl ammation and autoimmune process but not the grade of iron defi ciency, which was in agreement with the fi ndings of other authors. 27 Some authors reject the informative value of serum iron determination as a parameter of anemia in RA. 18 Our results indicate that serum iron refl ects the iron defi ciency and infl ammatory activity: the amount of serum iron was signifi cantly higher in healthy controls compared to RA (P = 0.014) ( Table  1) , and in the subgroup without anemia compared to the subgroup with anemia. These fi ndings confi rmed the hypoferremia condition in RA patients. Serum iron negatively correlated with IL-6 in healthy controls and in RA (Table 4) . We found a significant negative correlation of serum iron with CRP, ESR and DAS 28, which confi rms the relationship between the impaired iron metabolism and infl ammation in RA (Tables 4 and 6 ).
RESULTS
There is evidence that transferrin receptor modulates the expression of hepcidin. 28 Some authors propose the determination of serum prohepcidin as a new diagnostic index for ACD in RA. 29, 30 The available information in the scientifi c literature on the informative value of prohepcidin for evaluation of the iron status is rather confusing. [31] [32] [33] According to Kim et al. 31 serum prohepcidin correlates with the activity of the major disease process but not with the anemia condition. On the other hand, in another study 33 , the iron defi ciency in RA patients is related with the serum concentration of prohepcidin. The results obtained in our study indicated that the parameter was informative for evaluation of iron defi ciency and infl ammatory activity in RA: prohepcidin level was signifi cantly higher in RA patients (P = 0.013) ( Table 1 ) and refl ected hypoferremia condition in infl ammation since it positively correlated with sTfR and with CRP only in RA but not in the controls (Table 4) . Prohepcidin is also a sensitive parameter for disorders in RA expressed as its positive correlation with ESR, DAS 28 and RF (Table 5) . We didn't fi nd a correlation of prohepcidin with IL-6 which is probably due to the involvement of additional regulatory mechanisms in the conversion of the precursor prohepcidin in hepcidin. Our fi ndings indicate that the pro-infl ammatory markers CRP and IL-6 are associated with the changes in iron metabolism in RA since their levels are significantly higher in RA patients compared to controls (Tables 1 and  2 ). IL-6 is involved in autoimmunity by altering the balance between Th17 cells and Treg cells. IL-6 also acts on changing lipid concentrations in blood and on inducing the production of hepcidin which causes iron defi ciency. In conclusion, IL-6 is a major player in the pathogenesis of RA, and current evidence indicates that the blockade of IL-6 is a benefi cial therapy for RA patients. 3, 34 Our results confi rm the participation of IL-6 both in the hyposideremia (positive correlation with sTfR and negative with serum iron and Hb) (Tables 4 and 6) and in the infl ammatory and autoimmune disorders in RA (positive correlation of IL-6 with ESR, CRP and DAS 28) ( Table 5 ).
CONCLUSION
Our study shows that the simultaneous determination of two parameters, sTfR and prohepcidin, is most informative for evaluation of the changes in iron homeostasis in RA. The increase of both parameters provides information for tissue iron defi ciency (assessed by the level of sTfR), caused by the infl ammation when prohepcidin is expressed. This contention is confi rmed by the positive correlation of sTfR with prohepcidin only in RA but not in the healthy controls.
